A c c e p t e d M a n u s c r i p t 5 [20, 21] . Because persons with pertussis-like illness are often treated and HHMs receive prophylaxis before PCR results are available and because some states (including Wisconsin) have guidelines for antibiotic management of parapertussis [22, 23] 
METHODS

Case Reporting and Definitions
In Wisconsin, B. parapertussis infection is not officially reportable. Among A c c e p t e d M a n u s c r i p t 7
Data Analysis
Data were analyzed using SAS ® version 9.3 (SAS Institute, Inc., Cary, North Carolina).
Statewide, clinical characteristics of patients with parapertussis were summarized and stratified by age. Among Wood County patients, characteristics of parapertussis patients and pertussis patients were compared. Comparisons of clinical characteristics between groups on a categorical and continuous scale were conducted using chi-square tests (or Fisher's exact tests) and nonparametric Mann-Whitney U tests, respectively.
Because 98% of treatments and 100% of prophylaxes were with azithromycin, we limited our evaluation of antibiotics for parapertussis treatment and prevention to recipients of azithromycin treatment or azithromycin prophylaxis of any duration, compared with nonrecipients who received no antibiotics or received antibiotics not recommended for pertussis.
To investigate the effect of treatment on parapertussis illness duration, we compared characteristics of parapertussis patients by whether and when treatment was initiated.
Among parapertussis patient households, receipt of prophylaxis by a HHM was defined as having received azithromycin before any cough illness onset. In each household, the person with the earliest cough illness onset was considered the primary patient. Using the incubation period of pertussis (7-10 days; range: 4-21 days) [24], we compared attack rates (ARs) of coprimary and secondary cough illness (onsets 0-6 and 7-16 days after primary patient cough onset, respectively) among prophylaxis recipients with ARs among nonrecipients. Secondary cough illness was defined as onset 7-16 (rather than 7-28) days after primary patient cough onset A c c e p t e d M a n u s c r i p t 8 because 81% of households were followed for ≥16 days and only 57% were followed for ≥28 days.
To investigate effects of treatment and prophylaxis on prevention of secondary cough illnesses among parapertussis patient HHMs, we compared characteristics of households with and without secondary cough illnesses. To examine associations of treatment receipt by the household primary patient and prophylaxis receipt by HHMs with the presence of any secondary cough illnesses, we used multivariate log-binomial regression analysis accounting for repeated measurements (multiple HHMs) within the household on the basis of the generalized estimating equation approach. Potential confounders (HHM age and number of children aged <10 years in the household) were entered into the model individually, but were not included because they did not change associations by ≥10%. The final model included receipt of treatment by the household primary patient (no receipt, initiation <1 week or ≥1 week after cough onset) and receipt of prophylaxis by each HHM (no receipt, initiation <2 weeks or ≥2 weeks after cough onset in the household primary patient). Households with coprimary patients, unknown dates of cough onset, or unknown HHM antibiotic histories were excluded. Sensitivity analyses, adjusting for household follow-up time, produced similar results (data not displayed). Results were summarized as relative risks (RRs) with corresponding 95% confidence intervals (CIs). All Pvalues were 2-sided; P<.05 was used to define statistical significance. This project was reviewed by the Centers for Disease Control and Prevention and determined to be non-research because it was applied public health evaluation and control.
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RESULTS
Case Reporting and Inclusion
Parapertussis, Statewide
Among 218 patients with parapertussis, median age was 5.6 years (range: 1 month-39 years);
11% were aged <1 year; and 86% were aged <10 years ( Presence of paroxysmal cough, whoop and duration of cough were similar across all age groups ( Table 2 ). Reports of posttussive vomiting and apnea decreased with increasing patient age.
Coinfection, Statewide
Coinfected patients (n=13) were older (median age: 10.7 years; range: 7 months-55 years) than parapertussis patients ( A c c e p t e d M a n u s c r i p t
Parapertussis and Pertussis, Wood County
Among Wood County patients, parapertussis patients were younger than pertussis patients (median age: 5.3 versus 11.9 years; P <.001) ( Table 1) . Pertussis-like symptoms were reported frequently among parapertussis and pertussis patients, including paroxysmal cough (75% and 76%), posttussive vomiting (29% and 35%), whoop (29% and 15%), and sleep disturbance (78% and 77%), respectively ( Table 3 ). Among the 82% of parapertussis and 98% of pertussis patients followed until all symptoms resolved, median cough duration was longer among pertussis patients than parapertussis patients (28 versus 14 days; P = .004) ( Table 3) . Similarly, duration of paroxysmal cough was longer among pertussis patients. However, percentages of patients with illnesses meeting the pertussis clinical case definition did not differ significantly between parapertussis and pertussis patients (61% versus 74%; P = .177).
When stratified by age group, similar trends were observed; frequencies of pertussis-like symptoms were not significantly different among patients with parapertussis and pertussis, and durations of cough and paroxysmal cough tended to be longer among pertussis patients (Table   3) .
Antibiotics for Treatment, Statewide
Among parapertussis patients, 81% (154/190) of azithromycin treatment recipients and 88% (14/16) of nonrecipients were followed until coughing resolved. Among 150 (97%) treatment recipients with known initiation dates, 74 (49%), 42 (28%), and 34 (23%) received antibiotics 0-6, 7-13, and ≥14 days after cough onset, respectively. Patient ages were similar among treatment recipients and nonrecipients (Table 4) . Cough illnesses were shorter among patients treated 0-6
A c c e p t e d M a n u s c r i p t 12 days after cough onset, compared with nonrecipients (P = .002) and patients treated 7-13 and ≥14 days after cough onset (Table 4 ). Neither of the hospitalized patients received antibiotics 0-6 days after cough onset.
Antibiotics for Prevention, Statewide
The 218 parapertussis patients resided among 210 households; interviews were conducted with persons from 156 (74%) households, and 478 nonindex patient HHMs were identified. Antibiotic prophylaxis was received by 27% (131/478) of HHMs; all prophylaxes were with azithromycin.
Among HHMs aged 1-10 years, ARs of coprimary and secondary cough illnesses were significantly lower among prophylaxis recipients, compared with nonrecipients (Table 5 ).
Among HHMs aged >10 years, ARs of secondary cough illness were significantly lower among prophylaxis recipients. Additionally, among 12 HHMs aged <1 year, ARs were lower among prophylaxis recipients.
Households with and without secondary illnesses were similar regarding the number of HHMs aged <10 years, duration of follow-up, and treatment receipt by the household primary patient (Table 6 ). Prophylaxis receipt by HHMs was more frequent among households with no secondary cough illnesses (P = .086). Treatment (P = .046) and prophylaxis (P < .001) occurred significantly earlier during the primary patients' cough illnesses among households without secondary illnesses.
In multivariate analysis, compared with no prophylaxis, prophylaxis receipt by HHMs <2 weeks after primary patient cough onset was significantly associated with no secondary cough illnesses [15] . Consequently, parapertussis cases misclassified as pertussis might be perceived as vaccine failures [17] . Among 218 patients with parapertussis, 15 had specimens tested by using culture; of these, 5 had culture-results positive for B. parapertussis (2 were Wood County residents). Only 1 of 13 patients with coinfection had a specimen tested by using culture; neither species was isolated.
Among 103 Wood County patients with pertussis, 19 had specimens tested by using culture; all results were negative. Table 1 c Statewide, parapertussis patients were significantly younger than patients with coinfection (Mann-Whitney U test, P = .010). Among Wood County patients, parapertussis patients were significantly younger than pertussis patients (Mann-Whitney U test, P <.001).
TABLES
d Percentages exclude patients with missing information. b P-value of Mann-Whitney U test for differences in duration of cough illness by timing of initiation of azithromycin treatment: 0-6 days versus 7-13 days (P <.001); 0-6 days versus ≥14 days (P <.001); 7-13 days versus ≥14 days (P = .001). The primary patient in each household was excluded from these analyses.
a P-value of Fisher's exact test for difference in attack rate by receipt of azithromycin prophylaxis.
b Coprimary illness is defined as cough onset 0-6 days after cough onset in the household primary patient.
c Secondary illness is defined as cough onset 7-16 days after cough onset in the household primary patient. Attack rate calculations exclude from the denominator all persons with coprimary illnesses because persons with coprimary illnesses were not at risk for having a secondary illness. a Secondary cough illness is defined as cough onset in a household member 7-16 days after cough onset in the household primary patient.
b P-value of chi-square test or Fisher's exact test for categorical variables and Mann-Whitney U test for continuous variables.
c Adjusted for azithromycin prophylaxis of household members, azithromycin treatment of household primary patients, and for repeated measurements within each household.
